PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY	RECEIVED				
To: JOHN W. WALLEN, III JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003	PCT FEB 1 9 2002 NOTIFICATION OF TRANSMETAL OF THE INTERNATIONAL SEARCH REPORT. SECTION				
ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003	OR THE DECLARATION (PCT Rule 44.1) Date of Mailing				
	(day/month/year) 12 FEB 2002				
Applicant's or agent's file reference ORT-1489-PCT	FOR FURTHER ACTION See paragraphs 1 and 4 below				
International application No. PCT/US01/26373	International filing date (day/month/year) 24 August 2001 (24.08.2001)				
Applicant ORTHO-MCNEIL PHARMACEUTICAL, INC.	24 August 2001 (24-06-2001)				
1. The applicant is hereby notified that the international search report has been established and is transmitted herewith. Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):					
When? The time limit for filing such amendments is norm international search report; however, for more det	nally 2 months from the date of transmittal of the axis, see the notes on the accompany sheet.				
Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35					
For more detailed instructions, see the notes on d	he accompanying sheet.				
2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.					
3. With regard to the protest against payment of (an) additiona	el fee(s) under Rule 40.2, the applicant is notified that:				
the protest together with the decision thereon has been applicant's request to forward the texts of both the prot	transmitted to the International Bureau together with the test and the decision thereon to the designated Offices.				
no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.					
4. Further action(s): The applicant is reminded of the following:					
Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.					
Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).					
Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.					
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT	Authorized officer Gailene R. Gabel Authorized officer Gailene R. Gabel Authorized officer Authorized officer Authorized officer Authorized officer Authorized officer				
Washington, D.C. 20231 Facsimile No. (703)305-3230 Telephone No. (703) 308-0196					

Facsimile No. (703)305-3230 Form PCT/ISA/220 (July 1998)

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY						
To: JOHN W. WALLEN, III JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA	PCT NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT					
NEW BRUNSWICK, NJ 08933-7003	OR THE DECLARATION					
	(PCT Rule 44.1)					
	Date of Mailing (day/month/year) 12 FEB 2002					
Applicant's or agent's file reference ORT-1489-PCT	FOR FURTHER ACTION See paragraphs 1 and 4 below					
International application No. PCT/US01/26373	International filing date (day/month/year) 24 August 2001 (24.08.2001)					
Applicant	24 Magast 2001 (24.00.2001)					
ORTHO-MCNEIL PHARMACEUTICAL, INC.						
The applicant is hereby notified that the international search Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the clair	·					
When? The time limit for filing such amendments is nor international search report; however, for more d	mally 2 months from the date of transmittal of the etails, see the notes on the accompany sheet.					
Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	5					
For more detailed instructions, see the notes on	the accompanying sheet.					
The applicant is hereby notified that no international search Article 17(2)(a) to that effect is transmitted herewith.	report will be established and that the declaration under					
3. With regard to the protest against payment of (an) addition	nal fee(s) under Rule 40.2, the applicant is notified that:					
	n transmitted to the International Bureau together with the otest and the decision thereon to the designated Offices.					
no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.						
4. Further action(s): The applicant is reminded of the following:						
Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.						
Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).						
Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.						
Name and mailing address of the ISA/US	Authorized officer					
Commissioner of Patents and Trademarks Box PCT	Gailene R. Gabel Gailene R. Gabel Gailene R. Gabel					
Washington, D.C. 20231	Total and American					
Facsimile No. (703)305-3230	Telephone No. (703) 308-0196					

Facsimile No. (703)305-3230 Form PCT/ISA/220 (July 1998)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's ORT-1489-I	or agent's file reference PCT	FOR FURTHER ACTION		ication of Transmittal of International Search form PCT/ISA/220) as well as, where applicable, low.		
International PCT/US01/2	l application No. 26373	International filing date (day/mont) 24 August 2001 (24.08.2001)	 	(Earliest) Priority Date (day/month/year) 06 September 2000 (06.09.2000)		
Applicant ORTHO-MO	CNEIL PHARMACEUTICAL	,, INC.				
according to	This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.					
This interna	This international search report consists of a total of 3 sheets. It is also accompanied by a copy of each prior art document cited in this report.					
a. '						
b.	the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).					
	•	al application in written form.				
	· ·	national application in computer read	lable form.			
	• •	his Authority in written form.				
	furnished subsequently to th	his Authority in computer readable fo	m.			
	the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.					
	the statement that the information been furnished.	nation recorded in computer readable	e form is id	identical to the written sequence listing has		
2.	Certain claims were found	d unsearchable (See Box I).				
3. Wish	Unity of invention is lacking	ng (See Box II).				
4. With 1	regard to the title,	- total but she applicant				
	the text is approved as subm the text has been established	mitted by the applicant. d by this Authority to read as follows	s:			
5. With :	regard to the abstract,					
	the text is approved as subn	mitted by the applicant.				
				as it appears in Box III. The applicant may, ort, submit comments to this Authority.		
6. The fi	igure of the drawings to be pu	ublished with the abstract is Figure N	lo. <u>1</u>			
	as suggested by the applican		-	None of the figures		
	because the applicant failed	I to suggest a figure.				
	because this figure better characterizes the invention.					

Form PCT/ISA/210 (first sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

	PCT/US01/26373			
Box III TEXT OF THE ABSTRACT (Continuation of Item 5	of the first sheet)			
NEW ABSTRACT				
The present invention relates to a method for monitoring the effect of in vivo administration of cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (li), in particular the p10 li fragment, in blood of dosed patients. See Figure 1.				
·				
	•			
	·			
•				
	·			
•				
•				
	•			

Form PCT/ISA/210 (continuation of first sheet(2)) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/26373

		10110001120313			
	SSIFICATION OF SUBJECT MATTER				
IPC(7)	: G01N 33/535, 33/545				
US CL	: 435/7.24				
According to	International Patent Classification (IPC) or to both na	tional classification and IPC			
B. FIEL	DS SEARCHED				
Minimum do	Cumputation and the district of the contract o				
11 9 . 4	cumentation searched (classification system followed b	by classification symbols)	10.110.0		
0.3 4	35/7.2, 7.21, 7.23, 7.71, 7.92, 173.4, 173.7, 173.9, 2	(87.7, 904; 436/307, 308, 319, 172, 813;	424/9.2		
Documentation	on searched other than minimum documentation to the	extent that such documents are included i	n she fields seembed		
	on scarcica other than minimine documentation to the	extent that such documents are included i	ii die Heids searched		
F1					
Electronic da	ta base consulted during the international search (name	e of data base and, where practicable, sea	rch terms used)		
MEDLINE,	EMBASE, SCISEARCH, BIOSIS				
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		·		
Category *	Citation of document, with indication, where a		Relevant to claim No.		
X	WO 99/58153 A1 (BRIGHAM & WOMEN'S HOSF	PITAL) 18 November 1999	1-3		
	(18.11.1999), see entire document, especially pages	13-17.			
Y			4		
1					
Y	WO 97/40066 A1 (MASSACHUSETTS INSTITUTI	E of TECHNOLOGY) 30 October 1997	1-4		
	(30.10.1997), see entire document, especially pages		• •		
A/P	US 6,245,904 B1 (MELMS et al.) 12 June 2001 (12		1-4		
	1 00 0,243,304 B1 (MEDING & al.) 12 Julie 2001 (12		1-4		
A	119 5 010 620 A (UII DADUDENC ex et) 06 July 100	0 (06 07 1000) see entire decument			
, A	US 5,919,639 A (HUMPHREYS et al.) 06 July 1999	9 (00.07.1999), see entire document.	1-4		
Y	SITI C. D D				
1	SHI G.P. et. al. Role for cathepsin F in invariant ch		1-4		
	histocompatibility complex class II peptide loading b				
	Experimental Medicine. April 2000, vol. 191, No. 7	, pages 1177-1186, see abstract.			
	_				
Y	Database Medline ACCN, No. 1999:170289. Impai		1-4		
	antigen presentation and diminished collagen-induced				
1	Immunity. NAKAGAWA et al, see abstract, Fet	oruary 1999.	l		
			i l		
Frenchas	demonstrate and the state of th				
Further	documents are listed in the continuation of Box C.	See patent family annex.			
• s	pecial categories of cited documents:	"T" later document published after the inte	mational filing date or priority		
A document	defining the general state of the art which is not considered to be	date and not in conflict with the applic			
	that relevance	principle or theory underlying the invi	ention		
		"X" document of particular relevance; the	claimed invention cannot be		
"E" earlier ap	plication or patent published on or after the international filing date	considered novel or cannot be conside	red to involve an inventive step		
"L" document	t which may throw doubts on priority claim(s) or which is cited to	when the document is taken alone			
	the publication date of another citation or other special reason (as	"Y" document of particular relevance; the	claimed invention cannot be		
specified)		considered to involve an inventive ste	p when the document is		
"O" document	• — forming on an analysis discourse are supplied to the supplied of the suppl	combined with one or more other sucl			
	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in th	e an		
	published prior to the international filing date but later than the	"&" document member of the same patent	family		
	ate claimed	•			
Date of the actual completion of the international search Date of mailing of the international search report					
16 November 2001 (16 to 2001)					
	r 2001 (16.11.2001)	1.01.00	<u></u>		
Name and ma	Name and mailing address of the ISA/IIS Authorized officer				
	Commissioner of Patents and Trademarks Box PCT Washington, D.C. 2023 Foorimits No. (2003) 2020 Telephone No. (2003) 208-0196				
	Box PCT Washington, D.C. 20231 Gailene R. Gabel				
	(703)305-3230	Telephone No. (703) 308-0196			

Form PCT/ISA/210 (second sheet) (July 1998)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty and of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary emmination procedure, these is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

The claims only.

The description and the drawings may only be amended during international preliminary examination under Chapter II.

When ? Within 2 snooths from the date of transmittal of the international search seport or 16 snooths from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are secrived by the international Buresu after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/s filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confounded with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new:
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.